<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01358123</url>
  </required_header>
  <id_info>
    <org_study_id>vwfcirr</org_study_id>
    <nct_id>NCT01358123</nct_id>
  </id_info>
  <brief_title>Value of Von Willebrand Factor in Portal Hypertension</brief_title>
  <official_title>Von Willebrand Factor As Non-Invasive Predictor Of Clinically Significant Portal Hypertension And Mortality In Patients With Liver Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <brief_summary>
    <textblock>
      In patients with liver cirrhosis elevated levels of von Willebrand factor antigen (vWF-Ag)
      are found frequently but the clinical significance is unclear. vWF-Ag plays an important role
      in primary haemostasis and development of thrombotic vascular obliteration is discussed as a
      possible mechanism leading to portal hypertension. Invasive measurement of hepatic venous
      pressure gradient (HVPG) is the current gold standard for the diagnosis of portal
      hypertension. The investigators hypothesize that vWF-Ag levels in plasma may correlate with
      portal pressure and predict clinically significant portal hypertension (CSPH, HVPG &gt;=10mmHg)
      and its complications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with alcoholic, viral (chronic hepatitis C), and cryptogenic liver cirrhosis are
      included. Portal hemodynamics are assessed by HVPG measurement, vWF-Ag levels were measured
      by ELISA. Results will be compared. 3 and 6 months mortality will be recorded.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2006</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>von Willebrand Factor Ag Level</measure>
    <time_frame>at first visit (HVPG Measurement) (day 1)</time_frame>
    <description>von Willebrand Factor Antigen Levels are measured via ELISA and compared /corrlated to Hepatic Venous Pressure Gradient (HVPG). von Willebrand Factor Antigen levels are drawn and analyzed at the day of HVPG measurement. No follow up measurements will be performed, survival will be measured as secondary outcome parameter</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Mortality</measure>
    <time_frame>3 Months</time_frame>
    <description>Survival of Patients after index measurement of von Willebrand Factor and HVPG</description>
  </secondary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>Portal Hypertension</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with liver cirrhosis of all etioloiges, routinely scheduled for routine HVPG
        measurement will systematically be included during the study period
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Liver cirrhosis

        Exclusion Criteria:

          -  no HVPG measurement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>98 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnulf Ferlitsch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arnulf Ferlitsch, MD</last_name>
    <phone>+43140400</phone>
    <email>arnulf.ferlitsch@meduniwien.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnulf Ferlitsch</last_name>
      <phone>+436765666536</phone>
      <email>arnulf.ferlitsch@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Arnulf Ferlitsch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2011</study_first_submitted>
  <study_first_submitted_qc>May 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2011</study_first_posted>
  <last_update_submitted>September 24, 2015</last_update_submitted>
  <last_update_submitted_qc>September 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Arnulf Ferlitsch, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>liver cirrhosis</keyword>
  <keyword>portal hypertension</keyword>
  <keyword>survival</keyword>
  <keyword>von willebrand factor</keyword>
  <keyword>hepatic venous pressure gradient</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

